Table 1.

Completed phase I and phase II studies of ¹⁷⁷Lu-DOTATATE.

Study Reference	Number of Patients	Treatment Dose	Outcomes	Adverse Events
[25]	35	86% of patients received 600–800 mCi	37% response rate and 41% stable disease	Mild hair loss (49%), WHO G3 leukopenia (1%) and thrombocytopenia (4%)
[26]	51 (43 with GEP NETs)	22-30 Gbq	29.4% response rate and 59% stable disease	G1/G2 leukopenia (61%), anemia (78%) and thrombocytopenia (27%).
[27]	37	800 mCi	28% response rate, 41% stable disease and median PFS of 16.1 months	G2 hematologic toxicity (9.4%), G3 hematologic toxicity (12.5%) and G3 hepatic toxicity (9.4%)

Abbreviations: GEP NETs, gastroenteropancreatic neuroendocrine tumors; Gbq, gigabecquerel; mCi, millicurie; G, grade; PFS, progression-free survival